Keyphrases
Therapeutic Potential
100%
Fibrosis
100%
Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs)
100%
Peritoneal Dialysis
100%
Wharton's Jelly
100%
Methylglyoxal
87%
Peritoneal Fibrosis
50%
Peritoneal Dialysis Fluid
25%
Neoangiogenesis
25%
Peritoneum
25%
Inflammation
12%
Structural Change
12%
Stem Cell Properties
12%
Immunohistochemical Analysis
12%
Xenograft
12%
Inflammatory Response
12%
In Vivo Experiment
12%
Functional Impairment
12%
Rat Model
12%
Cytotoxic Effect
12%
Transplantation
12%
End-stage Renal Disease
12%
Continuous Ambulatory Peritoneal Dialysis
12%
Induced Cell Death
12%
Intraperitoneal Injection
12%
Intraperitoneal Administration
12%
Major Complications
12%
α-smooth muscle Actin (α-SMA)
12%
Eagle
12%
Long-term Hemodialysis
12%
Potential Therapeutic Strategies
12%
Peritoneal Macrophages
12%
Peritoneal Membrane
12%
Collagen Accumulation
12%
Medicine and Dentistry
Fibrosis
100%
Mesenchymal Stem Cell
100%
Peritoneal Dialysis
100%
Wharton Jelly
100%
Methylglyoxal
77%
Peritoneal Fibrosis
66%
Ultrafiltration
22%
Peritoneal Dialysis Fluid
22%
Intraperitoneal Drug Administration
22%
Peritoneum
22%
In Vitro
11%
Xenograft
11%
Serositis
11%
Cytotoxicity
11%
End Stage Renal Disease
11%
Continuous Ambulatory Peritoneal Dialysis
11%
Cell Death
11%
Mesothelial Cell
11%
Smooth Muscle Actin
11%
Stem Cell
11%
Functional Disease
11%
Immunology and Microbiology
Mesenchymal Stem Cell
100%
Wharton Jelly
100%
Peritoneal Dialysis
100%
Solution and Solubility
18%
Ultrafiltration
18%
Cytotoxicity
9%
Actin
9%
Xenograft
9%
Cell Death
9%
Inflammation Response
9%
Coculture
9%
Stem Cell
9%
Eagle
9%
Rat Model
9%
Smooth Muscle
9%
Continuous Ambulatory Peritoneal Dialysis
9%
Pharmacology, Toxicology and Pharmaceutical Science
Fibrosis
100%
Methylglyoxal
100%
Peritoneal Fibrosis
85%
Peritoneal Dialysis Fluid
28%
Inflammation
14%
End Stage Renal Disease
14%
Eagle
14%
Intraperitoneal Injection
14%
Rat Model
14%
Smooth Muscle Actin
14%
Functional Disease
14%
Cytotoxicity
14%